Breast Cancer Targeted therapy
There is also an emerging treatment method for breast cancer-targeted therapy. It is clinically found that about 2/5 of breast cancer patients express her2 (human epidermal growth factor receptor-2). The tumor cells of her2 positive breast cancer patients have amplified the gene encoding her2, which leads to the overexpression of her2 protein on the cell surface, and the cancer cells proliferate wildly. It is like a mouth for a person to eat. The more mouths, the more food they eat and the faster they grow. Therefore, her2-positive tumors are more malignant, progress faster, and are easier to relapse and metastasize. The disease-free survival period of patients is significantly shortened, and the prognosis is poor. It is the "most dangerous type of breast cancer."
Therefore, inhibiting her2 is like closing the mouth of cancer cells to eat. They cannot eat, and cancer cells are difficult to grow. This is the mechanism of breast cancer targeted therapy. Trastuzumab, a targeted therapy for her2 gene, has been in clinical use for more than ten years since 1998, and it has been proven to be an effective drug. Trastuzumab is a humanized antibody that can specifically bind to the protein receptor expressed by the gene her2 outside the tumor cell membrane, thereby blocking the information transmission channel of tumor cells and achieving the purpose of treating malignant tumors.
Breast cancer treatment: Targeted therapy has such a magical effect, so can all breast cancer patients use it? Of course not. The use of molecular targeted therapy is subject to strict conditions, and it is aimed at specific targets Just as a missile needs radar and satellites to help find and lock its target before launch, it also needs some auxiliary means. Targeted therapy has such a magical effect, so can all breast cancer patients use it? Of course not. The use of molecular targeted therapy is subject to strict conditions. It targets specific targets, just like missile launches. Just as radar and satellites are needed to help find and lock targets, it also needs some auxiliary means.
The patients receiving this treatment are all her2-positive breast cancer patients who have advanced recurrence or spread. Generally, the patients should use it after they have tried other traditional treatments and have failed. General screening of her2 positive patients who can be treated with biologically targeted drugs has greatly improved the patient's survival and quality of life. Once the her2 positive state is detected, the patient needs to take standardized and individualized treatment to avoid missed or misdiagnosed, choose the most appropriate treatment drugs and disease management plan, improve the cure rate, and reduce unnecessary medical costs.
Breast cancer endocrine therapy is a little strange to people compared with chemotherapy and radiotherapy, so what is the basis for breast cancer endocrine therapy? Breast cancer tumors, there is an estrogen receptor (er) or progesterone receptor (pr), Once the estrogen in the patient's body binds to these receptors, it will prevent the growth of tumor cells. Endocrine therapy is the use of drugs to block the binding of estrogen to these receptors or inhibit the production of estrogen, which can inhibit the growth of tumor cells, reduce the recurrence rate and the risk of metastasis. Therefore, the choice of endocrine therapy depends on whether the estrogen receptor is positive.
